SCHEMBL24928322

SCHEMBL24928322

CC(C)(C)OC(=O)NCCCSc1ccc(B(O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 9/20 0.44
CA2 P00918 9/20 0.44
CA12 O43570 7/20 0.44
CA9 Q16790 7/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
IDO1 P14902 2/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
SDCBP O00560 1/20 0.41
SDC2 P34741 1/20 0.41
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
MALT1 Q9UDY8 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28512058 0.84 LMNA (0.48) CA1CA2CA12CA9TDP1
SCHEMBL14558708 0.84 GAA (0.51) CA1CA2CA12CA9TDP1
SCHEMBL8795442 0.82 TDP1 (0.47) CA1CA2CA12CA9TDP1
SCHEMBL7894530 0.80 MTNR1A (0.48) CA1CA2CA12CA9TDP1
SCHEMBL18295921 0.79 L3MBTL1 (0.55) MEN1KMT2AIDO1LMNASDCBP
SCHEMBL22015112 0.79 ALDH1A1 (0.53) CA1CA2CA12CA9TDP1
SCHEMBL24671054 0.79 IDO1 (0.49) CA1CA2CA12CA9TDP1
SCHEMBL7527120 0.79 IDO1 (0.50) CA1CA2CA12CA9TDP1
SCHEMBL7528860 0.78 MTNR1A (0.62) MEN1KMT2AGAAIDO1LMNA
SCHEMBL10493712 0.78 TDP1 (0.49) CA1CA2CA12CA9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335569-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3 B Pharmaceuticals GmbH (DE) 2024-10-10 US disclosed
CN-117769443-A Fibroblast activation protein inhibitor and use thereof 3B制药有限公司 2024-03-26 CN disclosed
WO-2023002045-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-01-26 WO disclosed
EP-4122499-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335569-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF FIBP, FGF2, FGFR2 CA1 4360/4885CA2 1669/4885CA12 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.